ECSP21039816A - Anticuerpos monoclonales antirrábicos y cóctel de estos - Google Patents

Anticuerpos monoclonales antirrábicos y cóctel de estos

Info

Publication number
ECSP21039816A
ECSP21039816A ECSENADI202139816A ECDI202139816A ECSP21039816A EC SP21039816 A ECSP21039816 A EC SP21039816A EC SENADI202139816 A ECSENADI202139816 A EC SENADI202139816A EC DI202139816 A ECDI202139816 A EC DI202139816A EC SP21039816 A ECSP21039816 A EC SP21039816A
Authority
EC
Ecuador
Prior art keywords
rabies
cocktail
monoclonal antibodies
disclosure provides
monoclonal antibody
Prior art date
Application number
ECSENADI202139816A
Other languages
English (en)
Inventor
Sanjay Bandyopadhyay
Sanjeev Kumar Mendiratta
Pankaj Kalita
Kevinkumar Kansagra
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of ECSP21039816A publication Critical patent/ECSP21039816A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La descripción proporciona un anticuerpo monoclonal murino capaz de unirse y neutralizar la rabia o virus relacionados con la rabia. También proporciona un cóctel de al menos dos anticuerpos monoclonales con dichas propiedades. El cóctel puede neutralizar el virus que se deriva de especies tales como murciélagos, perros, vacas, mangostas, zorrillos y lobos y, por lo tanto, puede ser útil para tratar un paciente que potencialmente ha sido infectado. Además, la descripción proporciona una combinación de anticuerpo monoclonal murino o cóctel de al menos dos anticuerpos monoclonales y vacuna antirrábica para su uso en la profilaxis posexposición (PPE) a la rabia o virus relacionados con la rabia.
ECSENADI202139816A 2018-11-02 2021-06-02 Anticuerpos monoclonales antirrábicos y cóctel de estos ECSP21039816A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201821041598 2018-11-02

Publications (1)

Publication Number Publication Date
ECSP21039816A true ECSP21039816A (es) 2021-09-30

Family

ID=68655573

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202139816A ECSP21039816A (es) 2018-11-02 2021-06-02 Anticuerpos monoclonales antirrábicos y cóctel de estos

Country Status (9)

Country Link
EP (1) EP3873526B1 (es)
CN (1) CN113226372A (es)
BR (1) BR112021008240A2 (es)
EC (1) ECSP21039816A (es)
MA (1) MA54075A (es)
MX (1) MX2021005029A (es)
PE (1) PE20211056A1 (es)
PH (1) PH12021550987A1 (es)
WO (1) WO2020089742A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117771365B (zh) * 2023-12-07 2025-07-04 兰州生物制品研究所有限责任公司 一种抗狂犬病病毒组合单克隆抗体制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013048130A2 (ko) * 2011-09-30 2013-04-04 (주)셀트리온 광견병 바이러스를 중화시킬 수 있는 결합 분자
LT3220947T (lt) * 2014-11-18 2020-12-28 Humabs Biomed S.A. Antikūnai, galintys neutralizuoti pasiutligės virusą ir kitus lisavirusus bei jų panaudojimas
US10450367B2 (en) * 2015-08-13 2019-10-22 University Of Massachusetts Human antibodies against rabies and uses thereof

Also Published As

Publication number Publication date
MX2021005029A (es) 2021-07-15
PE20211056A1 (es) 2021-06-07
MA54075A (fr) 2022-02-09
EP3873526A1 (en) 2021-09-08
CN113226372A (zh) 2021-08-06
WO2020089742A1 (en) 2020-05-07
BR112021008240A2 (pt) 2021-10-26
PH12021550987A1 (en) 2021-11-08
EP3873526B1 (en) 2024-09-04

Similar Documents

Publication Publication Date Title
PH12018502673A1 (en) Anti-zika virus antibodies and methods of use
MY185320A (en) Human antibodies to influenza hemagglutinin
MX2017009716A (es) Anticuerpos humanos contra glicoproteina del virus ebola.
DOP2019000006A (es) Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos
EA201500854A1 (ru) Композиция, содержащая по меньшей мере две связывающие молекулы, нейтрализующие вирус гриппа а
GT201300093A (es) Compuestos antivirales
CL2019003393A1 (es) Virus oncolíticos y método.
PH12020551051A1 (en) Human antibodies to influenza hemagglutinin
CU24580B1 (es) Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas
CL2022002412A1 (es) Vacuna
EA201990010A1 (ru) Вакцина против вируса инфекционного бронхита
MX2019004029A (es) Compuestos y metodos para diagnosis y tratamiento de infecciones virales.
MX2018006416A (es) Metodos para el tratamiento, prevencion y diagnostico de infeccion por el virus de la diarrea epidemica porcina.
UY37449A (es) Anticuerpos anti-chikv y usos de éstos
BR112017016110A2 (pt) composições de imunoglobulina equina e usos para tratamento de doenças mediadas por filovírus
PH12018501750A1 (en) Porcine reproductive and respiratory syndrome vaccine virus
ECSP21039816A (es) Anticuerpos monoclonales antirrábicos y cóctel de estos
CO2022005281A2 (es) Anticuerpos antihemaglutinina y métodos de uso de estos
AR109291A1 (es) Clon de adnc del virus del síndrome reproductivo y respiratorio porcino y usos del mismo
GB2547835A (en) Protective material
HK1238655A1 (en) Human antibodies to influenza hemagglutinin
BR112018069193A2 (pt) uma vacina de combinação contra infecção por vírus pcv2 e prrs compreendendo albumina
EA201792083A1 (ru) Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний